DNMT3A and acute myeloid leukemia: Overall, the divergent aging‐related epigenetic trajectories observed in DNMT3A‐ and IDH2‐mutated AML align with clinical OS and treatment outcome, suggesting the involvement of aging‐related DNAm in the mutation‐specific AML pathobiology.